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Abstract
Chlamydia trachomatis (Ct) serological studies in populations could help monitor changes
in lifetime cumulative risk of infection. We developed a double-antigen sandwich ELISA
based on the Ct-specific Pgp3 antigen, then tested blind stored sera from over 800 partici-
pants in a New Zealand birth cohort from Dunedin at ages 26, 32 and 38. The double-anti-
gen sandwich ELISA was more sensitive than our previously characterised indirect Pgp3
ELISA. Pgp3 antibody was detected more often in women compared to men and correlated
with increasing numbers of sexual partners, self-reported Ct, and younger age at sexual
debut in both women and men. At age 26, 24.1% (99/411) of women were Pgp3 seroposi-
tive, as were 79.5% (35/44) of those reporting Ct infection; Pgp3 antibody persisted to age
38 in 96.5% (83/86). In men at age 26, the figures were 10.7% (47/442) and 25.0% (6/24),
respectively, with high (83.9%) antibody persistence to age 38. At age 38, among those
Pgp3 seropositive, 63.3% of women and 83.1% of men had not reported Ct infection. Thus,
Ct-specific Pgp3 antibody was detected in most women reporting Ct infection and corre-
lated with risk of infection in those who did not, with most infections remaining undetected.
As this antibody persisted for at least twelve years in 96% of these women, serology could
be used to evaluate Ct prevention programmes among women.
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Introduction
Chlamydia trachomatis (Ct) infection, if untreated in women, can result in pelvic inflammatory
disease, a condition leading to significant reproductive morbidity [1–3]. Opportunistic or
screening programmes have been recommended or implemented in several countries to reduce
prevalence and, subsequently, incidence and reproductive sequelae [4, 5], but their effective-
ness has never been confirmed by randomised controlled trials. While findings from the United
Kingdom (UK) screening programme (aimed at all those under 25 years) provide a measure of
current prevalence of those tested, a declining cumulative risk of infection would be a better
marker of success [6–8].
We previously produced an indirect lgG Enzyme Linked Immunosorbent Assay (ELISA) to
detect antibody to Ct-specific Pgp3 protein [9]. The Pgp3 protein is transcribed from the highly
conserved Ct plasmid [10] that is not found in human C. pneumoniae isolates [11]. Pgp3 is also
highly immunogenic in its native, trimeric form [12, 13] and antibody to Pgp3 does not cross
react with C. pneumoniae proteins with which Ct shares many similar genes [8]. We have dem-
onstrated the Pgp3 indirect ELISA is significantly more sensitive in detecting past Ct infection
than three of the most commonly used ELISAs [9]. We refer to sensitivity as the proportion of
individuals with past infection identified as positive by the assay i.e diagnostic sensitivity [14].
To maximise detection rates of past infection, we have developed a Pgp3 double-antigen sand-
wich ELISA, as has been done for other infections, including HIV-1, Hepatitis B and Hepatitis
E [15–17]. Double-antigen assays require that each protein-specific antibody recognises the
specific epitope of the antigen bound to an ELISA plate, as well as binding the same epitope on
labelled Pgp3, allowing detection of lower antibody titres [18].
In this report we describe the new ELISA, and demonstrate its enhanced performance over
other assays using the same samples that were originally used to validate our indirect assay [9].
We then examined Pgp3 antibody associations in participants of the New Zealand Dunedin
Multidisciplinary Health and Development Study (DMHDS), a birth cohort study in which
detailed information on sexual behaviour and health have been collected at regular intervals
from age 18–38 years [19]. Stored sera collected at ages 26, 32 and 38 years were tested by our
double-antigen ELISA, the findings compared with self-reported Ct infection and sexual
behaviour, and the persistence of the antibody response measured over this 12-year period
were determined.
Methods
Ct-positive and -negative control serum samples
Serum samples previously used to characterize our indirect ELISA [9] were available from 342
patients (including 182 men, 158 women and two of unknown sex) attending the Milne Centre,
Bristol and the Jefferiss Wing, London Genitourinary Medicine (GUM) clinics. All patients
had been diagnosed as Ct organism-positive at least one month previously.
The negative control sera were from 505 children aged between two and 13 years held at the
Department of Diagnostic Virology, Imperial College London. These children were assumed to
be Ct unexposed [9]. Ethical approval for the study was given by the South West—Central Bris-
tol Research Ethics Committee [05/Q2003/48].
Pgp3 double-antigen sandwich ELISA
Biotin-labelled Pgp3 was produced using the EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo
Scientific). Optimised assay conditions were determined by checkerboard titrations, as previ-
ously described [9]. Maxisorp microtitration plates (Nunc) were coated with unlabelled Pgp3
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with bovine serum albumin (BSA) in carbonate buffer, pH 9.6 (Sigma) at 4°C. The protein-
coated wells were blocked and stabilised by dilution buffer (PBS with 0.05% Tween-20 (PBST)
(Sigma) with 1% Hammersten casein (GE Healthcare)) containing 5% sucrose (Sigma). Bound
protein was incubated with either Pgp3 antibody-positive or negative defibrinated plasma [20]
(25μl) diluted in dilution buffer (75μl) containing BSA at 37°C. After washing with PBST, bioti-
nylated Pgp3 was added, incubated at 4°C, washed and incubated with horseradish peroxidase
(HRP)-labelled streptavidin (Thermo Scientific). Finally, HRP activity was measured with
TMB substrate (Biorad).
Assay cut-off was determined by receiver operating characteristic (ROC) analysis of absor-
bance (450–620nm) values on 505 paediatric samples and 342 samples from GUM patients,
previously used to characterize our indirect ELISA [9]. As before, we determined specificity on
the 494 samples from micro-immunofluorescence (MIF) assay-negative children [9].
Other Ct serology assays
The double-antigen assay performance was compared to our indirect IgG ELISA which takes
less operator time and less sample volume (1μl) [9], and to the Ct-IgG-pELISA plus Medac
assay (Medac, Wedel, Germany) [3, 9, 21, 22], the SeroCT-IgG ELISA (Savyon Diagnostics,
Ashdod, Israel) [3, 9, 22], the Ct IgG EIA (Ani Labsystems, Vantaa, Finland) [3, 7, 9, 22, 23]
and Ct antibody at 1 in 32 titre using the C. pneumonia IgG/IgMMIF test kit (Ani Labsystems,
Finland) [3, 9].
Epidemiological sample
This DMHDS was formed of 1037 children (539 males and 498 females) born in Dunedin,
New Zealand between April 1972 and March 1973, who participated in the first assessment at
the age of three [19]. Sexual health and behaviour information was collected at ages 18, 21, 26,
32 and 38, and sera were available from the last three assessments.
Information on sexual behaviour and sexually transmitted infections (STIs) was collected
by computerised questionnaire. Those reporting sexual intercourse were asked at age 21 about
ever having had an STI, and at ages 26, 32 and 38 if they had one since the previous assessment.
If an STI diagnosis was reported, the participant confirmed the specific infection, which was
assumed to be treated. At each assessment the participants were asked how many sexual part-
ners they had ever had. The total number of opposite and same-sex partners were combined at
each assessment and grouped as 0, 1, 2–4, 5–9, 10–19 and 20 or more. Age at first intercourse
was based on the first reported experience of vaginal intercourse or same-sex contact reported
at age 21. If none were reported by age 21, information given at age 38, when questions on first
heterosexual intercourse were repeated, was used [24].
Of the female cohort survivors, 83.2% (411/494) completed questionnaires on sexual behav-
iour and provided serum at the age 26 assessment, as did 87.8% (432/492) at the age 32 and
91.4% (448/490) at the age 38 assessments. Of the male survivors, 84.0% (441/525) at age 26,
85.9% (449/523) at age 32 and 87.0% (450/517) at age 38 did so. The sera were assayed for Ct
Pgp3 antibody by both the indirect and the double-antigen assays.
Ethical approvals for the early phases of the study were given by the Otago and the Southern
Regional Ethics Committee as relevant for each stage of the study and for the Phase (age) 38 by
the Lower South Regional Ethics Committee of the Ministry of Health [LRS/10/03/012]. Writ-
ten informed consent was obtained from the members of the DMHDS cohort.
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Data analysis
Data were analysed using STATA 13 statistical software. ROC analyses were carried out com-
paring results from the six different assays. Comparison of the Areas Under the Curves (AUC)
for the different assays followed procedures described in DeLong et al. [25]. These data were
programmed in Stata statistical software through the commands roccomp. P-values were
adjusted for multiple comparisons of AUCs using the Sidak method [26].
Population averaged generalised linear models for correlated binomial data with the probit
link were used to model the probability of a positive test result for a Ct-exposed patient (sensi-
tivity) according to gender for the different assays [27]. The same models were used for the
probabilities of negative test results for paediatric samples (specificity).
Pairwise comparisons were carried out as post-estimation calculations based on these mod-
els with 95% confidence intervals (CI) adjusted for multiple comparisons using the Scheffe
method [28].
Data from the Dunedin Study were analysed for the association of Ct Pgp3 antibody positiv-
ity with self-reported Ct and behaviour. Fisher's exact tests probed differences in proportions
of those testing Pgp3 antibody positive. In the supplementary analysis (Table D in S1 text), test-
ing by both the indirect and double-antigen ELISA was assessed and all who provided serum
were included.
A P-value of<0.05 was considered significant for all statistical tests.
Results
Pgp3 double-antigen ELISA
By ROC analysis, the Pgp3 double-antigen ELISA gives a significantly higher AUC than all
other assays assessed (p<0.0001–0.0002) (Table 1), facilitating discrimination between positive
and negative sera. This is confirmed by pairwise comparisons of sensitivities of the assays
(Table 2 and Tables A and B in S1 Text). A marked gender difference in the sensitivity of the
double-antigen ELISA was observed. Of the 158 GUM clinic samples from women, 131 (82.9%
[95% CI 77.0–88.8%]) were Ct-antibody positive (Table 2). This constitutes a 15.9% increase in
sensitivity over the indirect ELISA (71.5% [95% CI 64.5–78.6%]). In men, sensitivity was 54.4%
(95% CI 47.2–61.6%) (Table 2), a 15.0% increase over the indirect assay. In the 69 men with
only one episode of Ct and no history of urethritis the sensitivity was 42.6% (95% CI 31.6–
54.5%).
Specificity of the double-antigen ELISA, determined on 494 Ct-negative paediatric sera,
was 97.8% (95% CI 96.5–99.1%), the same as that for the indirect assay 97.8% (95% CI 96.5–
99.1%), and comparable with the commercial Major Outer Membrane Protein (MOMP) assays
(95% CI 94.7–99.0%) (Table 3 and Table C in S1 text).
Ct-specific Pgp3 antibodies in Dunedin Study samples
All Dunedin samples (n = 2641), including 10 for which there was no corresponding beha-
vioural information, were assayed by the double-antigen and, for direct comparison, the indi-
rect ELISAs (Table D in S1 Text). Of the 2365 samples that tested negative by the indirect, 243
were positive by the double-sandwich ELISA, consistent with the higher sensitivity of the new
assay. Of the samples that tested positive by the indirect (n = 276), 260 (94.2%) remained posi-
tive by the double-antigen ELISA. Of the 16 discordant samples, 11 (from six individuals) were
positive when assayed on an indirect ELISA without antigen present, hence those must have
been false-positives. The remaining five samples (from three individuals) originally positive
were negative by the second assay. This remains unexplained, although non-specific binding
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due to heterophilic antibodies and rheumatoid factor is a common occurrence in serological
assays [29]. The double-antigen ELISA detects nearly double (1.75 times) the number of self-
reported Ct cases compared to the indirect ELISA. Hence, only results from the double-antigen
ELISA were used for the following analysis.
At all ages, more women than men were Pgp3 antibody positive (Tables 4 and 5). The pro-
portion of seropositive women and men were, respectively, 24.1% and 10.7% (p<0.001) at age
26, 26.2% and 14.0% (p<0.001) at age 32, and 26.8% and 13.1% (p<0.001) at age 38. Among
women who self-reported Ct, the percentages seropositive at ages 26, 32 and 38 were 79.5%,
75.0% and 74.6%, respectively; all significantly (p<0.001) higher than those who had never
reported infection (Table 4). Among men self-reporting Ct by these ages, 25.0%, 33.3% and
27.0% were seropositive, respectively, again significantly higher than those who had undeclared
infection (p = 0.024, 0.001 and 0.009, respectively) (Table 5). At age 38, 19.6% of women and
11.9% of men who did not report an infection were seropositive (Tables 4 and 5). At age 38,
Table 1. Comparison of ROC analysis AUCs across the different assays.
Assay No. of samplesa ROC Area Mean (95% CI) Pr>chi2 Pr>chi2 (Sidak adjusted)
Pgp3 double antigen 846 0.819 (0.793–0.845)
Pgp3 indirect 846 0.774 (0.746–0.801) <0.0001 <0.0001
Anilabsystems 846 0.693 (0.665–0.721) <0.0001 <0.0001
SeroCT 846 0.718 (0.690–0.745) <0.0001 <0.0001
Medac 846 0.739 (0.712–0.766) <0.0001 <0.0001
MIF 846 0.766 (0.739–0.793) 0.0002 0.0011
aThe 505 paediatric and 341 GUM clinic samples were included in this analysis. One sample not tested by the Anilabsystems assay was not included.
doi:10.1371/journal.pone.0151497.t001
Table 2. Sensitivity of the Ct antibody assays according to gender.
Assay Positive samples/Total no. of
samples
No. of samples with discordant results %Sensitivity (95%
CI)
aPgp3 double antigen -ve
Assay +ve
bPgp3 double antigen +ve
Assay -ve
Female
Pgp3 double
antigen
131/158 - - 82.9 (77.0–88.8)
Pgp3 indirect 113/158 0 18 71.5 (64.5–78.6)
Anilabsystems 94/158 6 43 59.5 (51.8–67.1)
SeroCT 87/158 3 47 55.1 (47.3–62.8)
Medac 73/158 5 63 46.2 (38.4–54.0)
MIF 101/158 5 35 63.9 (56.4–71.4)
Male
Pgp3 double
antigen
99/182 - - 54.4 (47.2–61.6)
Pgp3 indirect 86/182 6 19 47.3 (40.0–54.5)
Anilabsystems 73/181 19 45 40.2 (33.1–47.4)
SeroCT 72/182 20 47 39.6 (32.5–46.7)
Medac 77/182 27 49 42.3 (35.1–49.5)
MIF 88/182 21 32 48.4 (41.1–55.6)
aThe numbers of samples giving negative results by the Pgp3 double antigen ELISA but positive results by each of the other assays.
bThe numbers of samples giving positive results by the Pgp3 double antigen ELISA but negative results by each of the other assays.
doi:10.1371/journal.pone.0151497.t002
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among seropositive individuals 63.3% (95% CI 54.4–71.4%) of women and 83.1% (95% CI
71.5–90.5%) of men gave no report of a Ct diagnosis (Tables 4 and 5).
The proportion of seropositive women and men increased significantly with lifetime num-
ber of sexual partners at all three ages (p<0.001) (Tables 4 and 5). Limiting this analysis to
Table 3. Specificities of the Ct antibody assays using true negative Ct control seraa
Negative samples/Total no. of samples Speciﬁcity (95% CI)
Pgp3 double antigen 483/494 97.8 (96.5–99.1)
Pgp3 indirect 483/494 97.8 (96.5–99.1)
Anilabsystems 489/494 99.0 (98.1–99.9)
SeroCT 479/494 97.0 (95.5–98.5)
Medac 468/494 94.7 (92.8–96.7)
MIF - -
aSpeciﬁcities were determined excluding the 11 paediatric samples positive by MIF assay.
doi:10.1371/journal.pone.0151497.t003
Table 4. The Relationship between Ct Pgp3 antibody positivity and self-reported Ct, number of sexual partners, number of sexual partners of
those who had not reported Ct infection and age of first coitus by age 26, 32 and 38 years. Women.
Age 26 years Age 32 years Age 38 years
Pgp3 +ve Total % (95% CI) Pgp3 +ve Total % (95% CI) Pgp3 +ve Total % (95% CI)
Total 99 411 24.1 (20.0–28.5) 113 432 26.2 (22.1–30.6) 120 448 26.8 (22.7–31.1)
Self-reported Ct by this age
Yes 35 44 79.5 (64.7–90.2) 39 52 75.0 (61.1–86.0) 44 59 74.6 (61.6–85.0)
No 63 360 17.5 (13.7–21.8) 74 377 19.6 (15.7–24.0) 76 387 19.6 (15.8–24.0)
p<0.001 p<0.001 p<0.001
Number of sexual partners
None 1 7 14.3 (0.4–57.9) 0 1 0.0 (0.0–0.96) 0 1 0.0 (0.0–0.96)
1 3 45 6.7 (1.4–18.3) 3 36 8.3 (1.8–22.5) 2 40 5.0 (0.6–16.9)
2–4 7 84 8.3 (3.4–16.4) 3 81 3.7 (0.8–10.4) 8 84 9.5 (4.2–17.9)
5–9 18 103 17.5 (10.7–26.2) 23 106 21.7 (14.3–30.6) 20 100 20.0 (12.7–29.2)
10–19 25 92 27.2 (18.4–37.4) 33 95 34.7 (25.2–45.2) 28 98 28.6 (19.9–38.6)
20 or more 44 75 58.7 (46.7–70.0) 49 102 48.0 (38.0–58.2) 59 117 50.4 (41.0–59.8)
p<0.001* p<0.001* p<0.001*
Number of sexual partners (if no previous self-report of Ct)
None 0 0 – 0 0 – 0 0 –
1 2 44 4.5 (0.6–15.5) 1 34 2.9 (0.1–15.3) 1 38 2.6 (0.1–13.8)
2–4 5 82 6.1 (2.0–13.7) 3 80 3.8 (0.8–10.6) 7 83 8.4 (3.5–16.6)
5–9 15 96 15.6 (9.0–24.5) 19 97 19.6 (12.2–28.9) 12 88 13.6 (7.2–22.6)
10–19 12 76 15.8 (8.4–26.0) 19 78 24.4 (15.3–35.4) 18 84 21.4 (13.2–31.7)
20 or more 28 57 49.1 (35.6–62.7) 30 79 38.0 (27.3–49.6) 36 88 40.9 (30.5–51.9)
p<0.001* p<0.001* p<0.001*
Age at ﬁrst coitus
< 16 years 54 133 40.6 (32.2–49.5) 59 139 42.4 (34.1–51.1) 60 142 42.3 (34.0–50.8)
16–17 years 33 158 20.8 (14.8–28.1) 36 167 21.6 (15.6–28.6) 40 175 22.9 (16.9–29.8)
> 17 years 12 120 10.0 (5.3–16.8) 18 126 14.3 (8.7–21.6) 20 131 15.3 (9.6–22.6)
p<0.001* p<0.001* p<0.001*
* χ2 test for trend
doi:10.1371/journal.pone.0151497.t004
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those who never reported a Ct diagnosis, again a significant trend (p = 0.001) in seropositivity
was found at all ages. At all ages, seropositivity was associated with younger first coitus in both
women and men (p<0.05). This association was stronger in women than in men and did not
vary by age, while in men the association weakened as they aged.
Pgp3 antibody persisted in most women and men over the 12-year study period (Fig 1).
Of the 86 women who did not report a subsequent diagnosis of Ct (suspected re-infection)
retested 12 years after their first positive test at age 26, 83 (96.5% [95% CI 90.1–99.3%])
remained seropositive. This included two who were weakly positive on ELISA at age 26 and
were negative at age 32. Of the 37 men retested after 12 years, 31 (83.8% [95% CI 68.0–93.8%])
remained seropositive. There was no significant difference between the percentage of men and
women remaining seropositive after 12 years (p = 0.12).
Discussion
In the epidemiological cohort, Pgp3 double-antigen ELISA positivity was associated with a his-
tory of self-reported Ct diagnosis, with the proportion seropositive higher in women self-
Table 5. The Relationship between Ct Pgp3 antibody positivity and self-reported Ct, number of sexual partners, number of sexual partners of
those who had not reported Ct infection and age of first coitus by age 26, 32 and 38 years. Men.
Age 26 years Age 32 years Age 38 years
Pgp3 +ve Total % (95% CI) Pgp3 +ve Total % (95% CI) Pgp3 +ve Total % (95% CI)
Total 47 441 10.7 (7.9–13.9) 63 449 14.0 (11.0–17.6) 59 450 13.1 (10.1–16.6)
Self-reported Ct by this age
Yes 6 24 25.0 (9.8–46.7) 11 33 33.3 (18.0–51.8) 10 37 27.0 (13.8–44.1)
No 41 404 10.1 (7.4–13.5) 52 412 12.6 (9.6–16.2) 49 413 11.9 (8.9–15.4)
P = 0.024 P = 0.001 P = 0.009
Number of sexual partners
None 0 9 0.0 (0.0–33.6) 0 2 0.0 (0.0–84.2) 0 1 0.0 (0.0–97.5)
1 0 35 0.0 (0.0–10.0) 1 22 4.5 (0.1–22.8) 2 27 7.4 (0.9–24.3)
2–4 5 76 6.6 (2.2–14.7) 4 55 7.3 (2.0–17.6) 5 54 9.3 (3.0–20.3)
5–9 8 100 8.0 (3.5–15.2) 9 102 8.8 (4.1–16.1) 7 87 8.0 (3.3–15.9)
10–19 13 106 12.3 (6.7–20.1) 13 96 13.5 (7.4–22.0) 10 112 8.9 (4.4–15.8)
20 or more 21 103 20.4 (13.1–29.5) 31 150 20.7 (14.5–28.0) 35 167 21.0 (15.1–27.9)
P<0.001* p<0.001* p<0.001*
Number of sexual partners (if no previous self-report of Ct)
None 0 0 – 0 0 – 0 1 0.0 (0.0–97.5)
1 0 35 0.0 (0.0–10.0) 1 22 4.5 (0.1–22.8) 0 24 0.0 (0.0–14.2)
2–4 5 75 6.7 (2.2–14.9) 2 53 3.8 (0.4–13.0) 4 52 7.7 (2.1–18.5)
5–9 8 98 8.2 (3.6–15.5) 8 98 8.2 (3.6–15.5) 7 82 8.5 (3.5–16.8)
10–19 13 100 13.0 (7.1–21.2) 13 91 14.3 (7.8–23.2) 9 106 8.5 (4.0–15.5)
20 or more 15 88 17.0 (9.9–26.6) 24 131 18.3 (12.1–26.0) 29 146 19.9 (13.7–27.3)
P = 0.001* p = 0.001* p<0.001*
Age at ﬁrst coitus
< 16 years 23 116 19.8 (13.0–28.3) 27 122 22.1 (15.1–30.5) 23 121 19.0 (12.4–27.1)
16–17 years 17 153 11.1 (6.6–17.2) 19 151 12.6 (7.7–19.0) 16 149 10.7 (6.3–16.9)
> 17 years 7 172 4.1 (1.7–8.2) 17 176 9.7 (5.7–15.0) 20 180 11.1 (6.9–16.6)
p<0.001* P = 0.003* P = 0.063*
* χ2 test for trend
doi:10.1371/journal.pone.0151497.t005
Chlamydia Pgp3 Antibody Epidemiology
PLOS ONE | DOI:10.1371/journal.pone.0151497 March 14, 2016 7 / 13
Fig 1. Flowchart showing the history of detectable Pgp3 antibody in women andmen at age 26, 32 and 38 years. The number of women and men
testing Pgp3 antibody positive at age 26 is given. Shown at age 32 and 38 are the numbers of these positive individuals who: i) maintained Pgp3
seropositivity with no self-report of re-exposure to Ct, ii) remained Pgp3 positive, but also reported a re-infection with Ct, iii) had become seronegative, and iv)
were missing at that time point. Finally, the numbers of women and men who became Pgp3 seropositive between age 26 and 32 together with their
subsequent antibody status and infection history by age 38 are shown.
doi:10.1371/journal.pone.0151497.g001
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reporting Ct than men. Seropositivity increased with increasing number of sexual partners
among those with and without a history of Ct, the latter suggesting undiagnosed Ct and/or
unreported Ct diagnoses. Of the seropositive women at age 26 years, 96.5% still had detectable
antibody after 12 years. While the numbers were relatively small, the results suggest more per-
sistence of antibody among women than men, and no major decline in seropositivity over this
period. Similar sensitivity was observed in women attending GUM clinics and in the Dunedin
cohort at age 26, but not in men making estimates of cumulative risk of Ct infection using
Pgp3 serology unreliable in men.
Well-characterised sera were used to determine assay sensitivity and specificity, enabling
direct comparison with the previously developed indirect Pgp3 ELISA and commercial MOMP
assays. We applied the assay to a cohort from which serial sera from the same individuals were
tested blind. Sexual behaviour and self-reported STIs (including Ct) were collected at each
assessment [19], reducing the risk of recall bias. Serum specimens were collected and stored
without incident at -80°C, so it is unlikely that antibodies would have decayed over time. The
cohort population tested in this study was broadly representative of the population in New
Zealand at the time of its formation, and had a very high retention at ages 26, 32 and 38 years
[30]. A weakness of this sample is that the number of people with a history of infection is small,
resulting in relatively wide confidence intervals around positivity rates. In addition, Ct infec-
tion in the cohort was based on self-reports which under-estimate the number of actual infec-
tions, as many will be asymptomatic and unlikely to seek testing [31, 32]. Alternatively, some
who report Ct infection may not have been infected.
Although the double-antigen ELISA demonstrated higher sensitivity than the indirect
ELISA, it requires a 25-fold higher volume of serum. In the initial analysis of Ct-exposed and
paediatric samples, no samples with indirect assay absorbance values<0.1 were positive when
assayed by the double-antigen ELISA, nor did any with values>1.0 test negative. Further anal-
yses of the Dunedin samples by the indirect ELISA (Table D in S1 Text) indicate that in large-
scale studies the indirect ELISA is suitable for initial screening, and subsequent testing (sera
with absorbance values between 0.1 and 1.0) by the double-antigen ELISA.
Public Health intervention strategies against Ct have been implicated in the rising number
of infections on the basis that they undermine the development of protective immunity [33,
34]. Our findings lead us to the conclusion that, if arrested immunity occurs following early
treatment, it does not substantially affect Pgp3 antibody development and persistence in
women [6, 33, 34]. At age 26 years we observed in women a similar high detection of Pgp3 anti-
body (~80%) in Ct detection-positive GUM attendees, who are more likely to be incident cases
[35], and the Dunedin cohort who are possibly more likely to be prevalent cases. Thus Pgp3
antibody could be used to estimate cumulative risk of infection in female populations in which
control programmes are taking place [6, 36]. In an accompanying paper, Woodhall et al. use
data and stored sera from nationally-representative household surveys from 1994 to 2012 in
England to evaluate, using Pgp3 antibody the impact of widespread opportunistic Ct screening
[36].
The higher proportion of women who are Pgp3 seropositive also holds true for MOMP pep-
tide serology [9, 21, 37]. The mechanism for this is unclear, and merits further investigation [9,
21]. We observed a lower Pgp3 sensitivity, 25%, in men in the Dunedin cohort than the 54.4%
observed in Ct detection-positive men attending GUM clinics. We believe the most likely
explanation is poor diagnostic test accuracy in the 1990s resulting in some men in the Dunedin
cohort being mis-diagnosed with Ct and/or recall bias [38]. If we consider only asymptomatic
men with no history of infection attending GUM clinics, probably many with incident infec-
tion [35], the observed 25% sensitivity remains lower than the 43% observed in this GUM pop-
ulation. This low sensitivity cannot be explained by the hypothesis that early Ct treatment
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stops the development of Pgp3 antibody, as this would be more likely to affect the asymptom-
atic men attending GUM clinics than those in the Dunedin cohort [33, 35].
The clear increase of Pgp3 positivity with increasing number of sexual partners, a major risk
factor for Ct and other STIs [39, 40], shows Pgp3 antibody can be used as a marker of Ct risk,
especially among women. That this correlation persisted when restricted to those who did not
report Ct is strong evidence for under-diagnosis and/or reporting in epidemiological studies,
although not all seropositive results will be due to Ct infection as the specificity of the test is
around 98%.
We observed that 63.3% women and 83.1% men who were seropositive at age 38 years did
not report having ever been diagnosed with Ct, while around 2% may be false positives, this
indicates that the majority of Ct infection was undetected/unreported in this cohort. Further-
more, there was an association of seropositivity with younger age of first sexual intercourse.
This probably reflects a greater cumulative risk of Ct infection [41], but could also be accentu-
ated by the possible increased biological susceptibility to Ct infection in younger women [42].
A key feature of this study was the repeated serological testing over a 12-year period.
Among women reporting any past infection, 79.5% at age 26, 75% at age 32 and 74.6% at age
38 were antibody positive. While we have no information on when individuals became infected
and could not examine the proportion of those who had seroconverted at some point in the
past with subsequent seroreversion [7], we demonstrate antibody persistence over a 12-year
period of 96.5% for women and 83.8% for men. While we excluded those reporting a subse-
quent Ct infection, we could not rule out unrecognised and/or reported reinfection that could
explain the two women who were initially seropositive, negative six years later, then again posi-
tive 12 years later. The finding of persistence is consistent with previous analyses in which
Pgp3 positivity in women was high soon after infection and remained stable at around 64%
after a year [7]. While the point estimates suggest lower persistence for men, our numbers
precluded examining this usefully. We are currently quantifying the loss of antibody since
time of treatment in women attending departments of sexual health. This information will be
used to develop the methodology in order to obtain estimates of Ct incidence and prevalence
in England using serial population-based serum collections.
Conclusion
We show Ct infection was both common and usually undetected in women in this New Zea-
land cohort born in 1972 and 1973, with almost a third of women by this age having been
infected by age 38, and demonstrate a strong and consistent correlation of Pgp3 seropositivity
with self-reported Ct, multiple sexual partners and age of first intercourse. We conclude that
our simple indirect assay facilitates high through-put antibody screening, and equivocal speci-
mens can then be reconciled by the double-antigen ELISA.
Our findings suggest that surveys could make use of Pgp3 antibody in different age groups
to examine the temporal change in cumulative risk of infection particularly among women,
although persistence beyond 12 years has not yet been investigated [36]. These data provide a
powerful argument for a role for Ct Pgp3 serology in evaluating Ct control programmes [36].
Supporting Information
S1 Text. Additional tables and text comparing the performance of the indirect and double-
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